Research prototype, not medical advice.

In a phase I/II trial, allogeneic mesenchymal stem cell infusions for frailty had acceptable safety and signs of functional improvement (small sample).

Confidence
Speculative
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Stem cell exhaustionAllogeneic mesenchymal stem cell infusion

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty
Golpanian et al. · The Journals of Gerontology: Series A 2017
— Verified